Straits Times Index
3,304.21 +31.49 (+0.96%) Nikkei
38,424.84 +872.68 (+2.32%) Hang Seng
17,161.41 +332.48 (+1.98%) FTSE 100
8,044.81 +20.94 (+0.26%) Bitcoin USD
66,827.26 +493.12 (+0.74%) CMC Crypto 200
1,441.51 +26.76 (+1.89%)
Atossa Therapeutics, Inc. (ATOS)
After hours:
| Previous close | 1.4200 |
| Open | 1.4100 |
| Bid | 1.4700 x 800 |
| Ask | 1.5000 x 1600 |
| Day's range | 1.4100 - 1.5100 |
| 52-week range | 0.5900 - 2.3100 |
| Volume | |
| Avg. volume | 1,654,975 |
| Market cap | 186.703M |
| Beta (5Y monthly) | 1.24 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2400 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.58 |
GlobeNewswireAtossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
SEATTLE, April 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) and Quantum Leap Healthcare Collaborative™ today announced the initiation of a new study to evaluate Atossa’s proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO®), a cyclin-dependent kinase (CDK) 4/6 inhibitor marketed by Eli Lilly and Company, in women with ER+/HER2- breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines i
- GlobeNewswire
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that Chief Executive Officer Steven Quay, M.D., Ph.D., will speak at the Noble Capital Markets Emerging Growth Healthcare Conference on Wednesday, April 17 at 9:00 am ET. The presentation will be available virtually and members of the Company’s leadership team will be available for one-on-one meetings with registered investors of the conference. Atossa is a clinical st
- GlobeNewswire
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced promising safety and efficacy data from the Company’s Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) clinical trial. The EVANGELINE study is evaluating (Z)-endoxifen as a neoadjuvant treatment for pre-menopausal women with Grade 1 or 2 Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. Atossa is a cli
